PDCD1 and neoplasm: This effect can be augmented by the use of a nanosized radioenhancer (NBTXR3), even going so far as to enable IRT to effectively overcome anti-PD1 antibody (αPD1) resistance, leading to tumor recession outside the radiated site (the so-called “abscopal effect”) in an αPD1-resistant murine lung cancer model (4).